Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: Current hurdles and future perspectives
- 1 April 2014
- journal article
- Published by Elsevier BV in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1845 (2), 266-276
- https://doi.org/10.1016/j.bbcan.2014.02.005
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium studyThe Lancet Oncology, 2013
- Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: A predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomasEuropean Journal of Cancer, 2012
- Dynamic analysis of lung metastasis by mouse osteosarcoma LM8: VEGF is a candidate for anti-metastasis therapyClinical & Experimental Metastasis, 2012
- New Systemic Therapy Options for Advanced SarcomasCurrent Treatment Options in Oncology, 2012
- An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumorsCancer Chemotherapy and Pharmacology, 2012
- Understanding resistance to EGFR inhibitors—impact on future treatment strategiesNature Reviews Clinical Oncology, 2010
- Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort studyThe Lancet Oncology, 2010
- Angiogenesis and vascular targeting in Ewing sarcomaCancer, 2009
- Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumorsCancer, 2008
- Evidence for activation of KIT, PDGFRα, and PDGFRβ receptors in the Ewing sarcoma family of tumorsCancer, 2007